Analysis of influencing factors on the inclusion of Chinese patent medicines in the national reimbursement drug list

CAO Shihuan; LIANG Wanxian; ZHANG Lining; GUAN Haijing; JIN Xuejing

doi:10.6039/j.issn.1001-0408.2024.22.01

您当前的位置：

首页 >

文章列表页 >

Analysis of influencing factors on the inclusion of Chinese patent medicines in the national reimbursement drug list

更新时间：2025-09-24

- Analysis of influencing factors on the inclusion of Chinese patent medicines in the national reimbursement drug list
- ZHONGGUO YAOFANG Vol. 35, Issue 22, Pages: 2709-2715(2024)
- 作者机构：
  
  1.北京中医药大学中医学院，北京　100029
  2.北京中医药大学循证医学中心，北京　100029
  3.北京中医药大学国际循证中医药研究院，北京　100029
  4.首都医科大学附属北京天坛医院药学部，北京　100070
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.22.01
  CLC： R95
- Received：20 June 2024，
  
  Revised：2024-10-28，
  
  Accepted：28 October 2024，
  
  Published：30 November 2024
- 稿件说明：
移动端阅览
曹世欢,梁婉娴,张丽宁,等.中成药医保准入的影响因素分析[J].中国药房,2024,35(22):2709-2715.

CAO Shihuan,LIANG Wanxian,ZHANG Lining,et al.Analysis of influencing factors on the inclusion of Chinese patent medicines in the national reimbursement drug list[J].ZHONGGUO YAOFANG,2024,35(22):2709-2715.
曹世欢,梁婉娴,张丽宁,等.中成药医保准入的影响因素分析[J].中国药房,2024,35(22):2709-2715. DOI： 10.6039/j.issn.1001-0408.2024.22.01.

CAO Shihuan,LIANG Wanxian,ZHANG Lining,et al.Analysis of influencing factors on the inclusion of Chinese patent medicines in the national reimbursement drug list[J].ZHONGGUO YAOFANG,2024,35(22):2709-2715. DOI： 10.6039/j.issn.1001-0408.2024.22.01.

摘要

目的

分析影响中成药在国家医保目录准入的因素，助力中成药在医保准入中充分体现实际价值。

方法

从国家医保局官网获取2021－2023年通过形式审查的目录外中成药的申报材料，包括药品的基本信息、安全性、有效性、创新与传承信息，并参考药典和药智网等进行补充；经济性信息和企业信息通过药智网等网站获取。对药品的首次申报信息和准入结果进行单因素分析、多因素Logistic回归分析和逐步回归分析；并将在不同年份进行多次申报的药品均作为独立样本进行敏感性分析。结果与

结论

2021－2023年通过形式审查的目录外中成药有27个，涉及37次申报。单因素分析结果显示，药品说明书中适应证/功能主治描述中含有中医证型、有明确的特殊人群用药方案调整信息、上市时间短、注册类型为1～6类中成药或Ⅰ类中药创新药/Ⅲ类古代经典名方中药复方制剂、生产企业申报当年在“中国医药工业百强企业榜单”的中成药更有可能进入国家医保目录（

＜0.05）；多因素Logistic回归分析结果显示差异暂不显著，逐步回归与单因素分析的结果显示出较好的一致性。敏感性分析结果与基础分析呈现出相同趋势。建议中成药企业进一步明确对产品说明书内容的描述，增强创新能力，传承发展古代经典名方，并及时完善临床试验证据。

Abstract

OBJECTIVE

To analyze the factors affecting the inclusion of Chinese patent medicines in China’s National reimbursement drug list （NRDL）， and assist these medicines in fully reflecting their actual value in the reimbursement admission process.

METHODS

From the official website of the China’s National Healthcare Security Administration， the application materials of Chinese patent medicines outside the list that passed the formal review from 2021 to 2023 were obtained， including basic information on the medicines， safety， efficacy， innovation and heritage information， and supplemented with references from the pharmacopeia

and the Yaozhi Database. Economic information and enterprise information were obtained through websites such as the Yaozhi Database. Univariate analysis， multivariat

e Logistic regression analysis and stepwise regression analysis were conducted on the initial application information and admission outcomes of the medicines. Sensitivity analysis was also performed on medicines that applied multiple times in different years as independent samples. RESULTS

CONCLUSIONS

There were 27 Chinese patent medicines that passed the formal review from 2021 to 2023， involving 37 applications. The univariate analysis results showed that medicines with descriptions of traditional Chinese medicine （TCM） syndrome types， clear adjustment information for medication plans for specific population groups， short time to market in the indications of the package insert， registered as Class 1 to 6 following or class Ⅰ innovative TCM/class Ⅲ ancient classic prescription compound TCM registered， and those produced by enterprises listed in the “Top 100 Chinese Pharmaceutical Industry Enterprises” list for the current year were more likely to be included in the NRDL （

＜0.05）. The results of the multivariate Logistic regression analysis were not statistically significant， but the stepwise regression results indicated good consistency with the univariate analysis. The results of the sensitivity analysis were consistent with the trend of basic analysis. It is recommended that Chinese patent medicine enterprises further clarify the description of product instructions， expand innovation capabilities， inherit and develop ancient classic prescriptions， and promptly complete clinical trial evidence.

关键词

Keywords

references

丁锦希，李轶，韩晓睿，等 . 国家医保目录动态调整机制的改革成效与发展思路 [J ] . 中国医疗保险， 2021 （ 5 ）： 40 - 46 .

DING J X ， LI Y ， HAN X R ， et al . The reform effect and development ideas of the dynamic adjustment mechanism for Chinese national drug reimbursement list [J ] . China Health Insur ， 2021 （ 5 ）： 40 - 46 .

国家医疗保障局 . 国家医疗保障局关于公布《2023年国家基本医疗保险、工伤保险和生育保险药品目录调整工作方案》及申报指南的公告 [EB/OL ] .（ 2023-06-29 ）[ 2024-06-04 ] . https：//www.gov.cn/zhengce/zhengceku/202306/content_6889132.htm https://www.gov.cn/zhengce/zhengceku/202306/content_6889132.htm .

National Healthcare Security Administration . Announcement of the National Healthcare Security Administration on the Work Plan for Adjusting National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List 2023 and declaration guidelines [EB/OL ] .（ 2023-06-29 ）[ 2024-06-04 ] . https：//www.gov.cn/zhengce/zhengceku/202306/content_6889132.htm https://www.gov.cn/zhengce/zhengceku/202306/content_6889132.htm .

国家医疗保障局 . 国家医疗保障局关于公布《2022年国家基本医疗保险、工伤保险和生育保险药品目录调整工作方案》及相关文件的公告 [EB/OL ] .（ 2022-06-29 ）[ 2024-06-04 ] . https：//www.gov.cn/zhengce/zhengceku/2022-06/30/content_5698559.htm https://www.gov.cn/zhengce/zhengceku/2022-06/30/content_5698559.htm .

National Healthcare Security Administration . Announcement of the National Healthcare Security Administration on the Work Plan for Adjusting National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List 2022 and relevant files [EB/OL ] .（ 2022-06-29 ）[ 2024-06-04 ] . https：//www.gov.cn/zhengce/zhengceku/2022-06/30/content_5698559.htm https://www.gov.cn/zhengce/zhengceku/2022-06/30/content_5698559.htm .

国家医疗保障局 . 国家医疗保障局关于公布《2021年国家医保药品目录调整工作方案》和《2021年国家医保药品目录调整申报指南》的公告 [EB/OL ] .（ 2021-06-30 ）[ 2024-06-04 ] . http：//www.nhsa.gov.cn/art/2021/6/30/art_109_6616.html http://www.nhsa.gov.cn/art/2021/6/30/art_109_6616.html .

National Healthcare Security Administration . Announcement of the National Healthcare Security Administration on the Work Plan for Adjusting and National Reimbursement Drug List 2021 and Declaration Guidelines for Adjusting and National Reimbursement Drug List 2021 [EB/OL ] .（ 2021-06-30 ）[ 2024-06-04 ] . http：//www.nhsa.gov.cn/art/2021/6/30/art_109_6616.html http://www.nhsa.gov.cn/art/2021/6/30/art_109_6616.html .

高悦，杨林 . 2020年版及2019年版国家医保药品目录收载药品数量对比 [J ] . 中国药业， 2022 ， 31 （ 12 ）： 38 - 41 .

GAO Y ， YANG L . Comparison of quantity of medicines included in the 2019 edition and 2020 edition of catalog of medicines covered by national medical insurance system [J ] . China Pharm ， 2022 ， 31 （ 12 ）： 38 - 41 .

郭凌云，李瑞锋，马爽 . 纵向视角下我国中成药和中药饮片医保药品目录管理研究 [J ] . 中国医疗保险， 2024 （ 3 ）： 44 - 50 .

GUO L Y ， LI R F ， MA S . Study on the national healthcare security drug catalog management of proprietary Chinese medicines and Chinese medicinal tablets from a vertical perspective [J ] . China Health Insur ， 2024 （ 3 ）： 44 - 50 .

侯鸿军，王莉，李兴民，等 . 我国中成药说明书现状、存在问题及对策建议 [J ] . 中国食品药品监管， 2020 （ 2 ）： 32 - 39 .

HOU H J ， WANG L ， LI X M ， et al . Current situation，exis-ting problems and countermeasures of Chinese patent medicine instructions in China [J ] . China Food Drug Adm Mag ， 2020 （ 2 ）： 32 - 39 .

国家医疗保障局 . 关于公示2021年国家医保药品目录调整通过初步形式审查药品及信息的公告 [EB/OL ] .（ 2021-07-30 ）[ 2024-06-04 ] . http：//www.nhsa.gov.cn/art/2021/7/30/art_109_6619.html http://www.nhsa.gov.cn/art/2021/7/30/art_109_6619.html .

National Healthcare Security Administration . Announcement on the preliminary formal review of drugs and information for the national reimbursement drug list 2021 adjusting [EB/OL ] .（ 2021-07-30 ）[ 2024-06-04 ] . http：//www.nhsa.gov.cn/art/2021/7/30/art_109_6619.html http://www.nhsa.gov.cn/art/2021/7/30/art_109_6619.html .

国家医疗保障局 . 关于公示2022年国家基本医疗保险、工伤保险和生育保险药品目录调整通过初步形式审查的药品及相关信息的公告 [EB/OL ] .（ 2022-09-06 ）[ 2024-06-04 ] . http：//www.nhsa.gov.cn/art/2021/7/30/art_109_6619.html http://www.nhsa.gov.cn/art/2021/7/30/art_109_6619.html .

National Healthcare Security Administration . Announcement on the preliminary formal review of drugs and information for the national basic medical insurance， work injury insurance， and maternity insurance drug list 2022 adjusting [EB/OL ] .（ 2022-09-06 ）[ 2024-06-04 ] . http：//www.nhsa.gov.cn/art/2021/7/30/art_109_6619.html http://www.nhsa.gov.cn/art/2021/7/30/art_109_6619.html .

国家医疗保障局 . 关于公示2023年国家基本医疗保险、工伤保险和生育保险药品目录调整通过初步形式审查的药品及相关信息的公告 [EB/OL ] .（ 2023-08-18 ）[ 2024-06-04 ] . http：//www.nhsa.gov.cn/art/2023/8/18/art_109_11184.html http://www.nhsa.gov.cn/art/2023/8/18/art_109_11184.html .

National Healthcare Security Administration . Announcement on the preliminary formal review of drugs and information for the national basic medical insurance， work injury insurance， and maternity insurance drug list 2023 adjusting [EB/OL ] .（ 2023-08-18 ）[ 2024-06-04 ] . http：//www.nhsa.gov.cn/art/2023/8/18/art_109_11184.html http://www.nhsa.gov.cn/art/2023/8/18/art_109_11184.html .

国家医疗保障局，人力资源社会保障部 . 国家医保局　人力资源社会保障部关于印发《国家基本医疗保险、工伤保险和生育保险药品目录（2021年）》的通知 [EB/OL ] .（ 2021-11-24 ）[ 2024-06-04 ] . https：//www.gov.cn/zhengce/zhengceku/2021-12/03/content_5655651.htm https://www.gov.cn/zhengce/zhengceku/2021-12/03/content_5655651.htm .

National Healthcare Security Administration，Ministry of Human Resources and Social Security . Notice from National He althcare Security Administration and Ministry of Human Resources and Social Security on issuing the National Basic Medical Insurance ， Work Injury Insurance ， and Maternity Insurance Drug List 2021 [EB/OL ] .（ 2021-11-24 ）[ 2024-06-04 ] . https：//www.gov.cn/zhengce/zhengceku/2021-12/03/content_5655651.htm https://www.gov.cn/zhengce/zhengceku/2021-12/03/content_5655651.htm .

国家医疗保障局，人力资源社会保障部 . 国家医保局　人力资源社会保障部关于印发《国家基本医疗保险、工伤保险和生育保险药品目录（2022年）》的通知 [EB/OL ] .（ 2023-01-13 ）[ 2024-06-04 ] . http：//www.nhsa.gov.cn/art/2023/1/18/art_104_10078.html http://www.nhsa.gov.cn/art/2023/1/18/art_104_10078.html .

National Healthcare Security Administration，Ministry of Human Resources and Social Security . Notice from National Healthcare Security Administration and Ministry of Human Resources and Social Security on issuing the National Basic Medical Insurance ， Work Injury Insurance ， and Maternity Insurance Drug List 2022 [EB/OL ] .（ 2023-01-13 ）[ 2024-06-04 ] . http：//www.nhsa.gov.cn/art/2023/1/18/art_104_10078.html http://www.nhsa.gov.cn/art/2023/1/18/art_104_10078.html .

国家医疗保障局，人力资源社会保障部 . 国家医保局　人力资源社会保障部关于印发《国家基本医疗保险、工伤保险和生育保险药品目录（2023年）》的通知 [EB/OL ] .（ 2023-12-07 ）[ 2024-06-04 ] . http：//www.nhsa.gov.cn/art/2023/12/13/art_53_11674.html http://www.nhsa.gov.cn/art/2023/12/13/art_53_11674.html .

National Healthcare Security Administration，Ministry of Human Resources and Social Security . Notice from National Healthcare Security Administration and Ministry of Human Resources and Social Security on issuing the National Basic Medical Insurance ， Work Injury Insurance ， and Maternity Insurance Drug List 2023 [EB/OL ] .（ 2023-12-07 ）[ 2024-06-04 ] . http：//www.nhsa.gov.cn/art/2023/12/13/art_53_11674.html http://www.nhsa.gov.cn/art/2023/12/13/art_53_11674.html .

刘国恩 . 中国药物经济学评价指南2020 [M ] . 北京：中国市场出版社， 2020 ： 11 - 12 .

LIU G E . China guidelines for pharmacoeconomic evaluations 2020 [M ] . Beijing ： China Market Press ， 2020 ： 11 - 12 .

Views

289

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical efficacy and influencing factors of ceftazidime and avibactam monotherapy versus combination therapy in the treatment of CRGNB infection

Study on the influential factors for clinical efficacy of polymyxin B combined with other antibiotics in the treatment of carbapenem-resistant Acinetobacter baumannii pulmonary infection

Investigation on the current status of pharmaceutical care in medical institutions in China

Analysis of the standardization and influential factors in the prevention and treatment of glucocorticoid-induced osteoporosis with drugs

Characteristics and influencing factors of immune-related adverse events in patients with extensive-stage small cell lung cancer treated with immune checkpoint inhibitors

Related Author

LIU Changwei

WANG Xiaohua

ZHANG Hui

WANG Ranran

XIAO Rongcheng

FANG Ling

DU Mei

TAN Ruijuan

Related Institution

Dept. of Infectious Diseases， the First Affiliated Hospital of Anhui Medical University

Grade Ⅲ Pharmaceutical Chemistry Laboratory of TCM， National Administration of Traditional Chinese Medicine

Dept. of Pharmacy， the First Affiliated Hospital of Anhui Medical University

Dept. of Rehabilitation Medicine， Hengshui Municipal People’s Hospital

Dept. of Pharmacy， Hengshui Municipal People’s Hospital

⁰